Drug Regulator Seeks Answers on Unapproved Medicines in National Formulary of India

The Drug Controller General of India (DCGI) has raised significant concerns about the latest edition of the National Formulary of India (NFI 2026), which reportedly includes several drugs not approved by the Central Drugs Standard Control Organisation (CDSCO). In response to these discrepancies, the DCGI has formally communicated with the Indian Pharmacopoeia Commission (IPC), seeking a detailed explanation.

The National Formulary of India serves as a crucial reference document for medical practitioners across the country, providing comprehensive information on drugs, their formulations, dosages, and usage. Its primary goal is to promote rational use of medicines and standardize treatment protocols. Therefore, the inclusion of unapproved drugs in such a pivotal guide poses potential risks to public health and patient safety, as it might inadvertently lead to the prescription and use of medications that have not undergone the necessary rigorous regulatory scrutiny and approval processes.

Understanding the Key Players

• Drug Controller General of India (DCGI): This is the head of the Central Drugs Standard Control Organisation (CDSCO), responsible for approval of new drugs, clinical trials, and setting standards for drug manufacturing, sales, and import in India.
• Central Drugs Standard Control Organisation (CDSCO): India's principal regulatory body for pharmaceuticals and medical devices, ensuring the quality, safety, and efficacy of drugs.
• Indian Pharmacopoeia Commission (IPC): An autonomous institution under the Ministry of Health & Family Welfare, Government of India. It is responsible for setting standards for drugs in India by publishing the Indian Pharmacopoeia and the National Formulary of India, ensuring the quality and safety of medicines.

The core issue revolves around the fact that any drug listed in an official formulary like the NFI is generally presumed to have met all regulatory requirements, including approval from the CDSCO. The DCGI's query to the IPC highlights a serious lapse if drugs without CDSCO approval have indeed been incorporated into NFI 2026.

Beyond the regulatory concerns, stakeholders in the healthcare sector have also voiced complaints regarding the unavailability of the online version of NFI 2026. In today's digital age, easy and quick access to such essential information is paramount for healthcare professionals to make informed decisions. The absence of an online edition further complicates matters, potentially limiting the reach and utility of the formulary, especially when such critical inaccuracies are being reported.

The outcome of the DCGI's inquiry to the IPC will be closely watched, as it could have significant implications for drug regulation, professional medical guidance, and ultimately, public health in India. Ensuring that all listed drugs are properly vetted and approved is fundamental to maintaining trust in the country's pharmaceutical standards.

This report is for informational purposes only and should not be considered medical or professional advice. Always consult a qualified healthcare professional for health-related decisions.